Asada Hidetsugu, Kishida Tsunao, Hirai Hideyo, Shin-Ya Masaharu, Imanishi Jiro, Takeuchi Minoru, Mazda Osam
Department of Biotechnology, Faculty of Engineering, Kyoto Sangyo University, Kyoto 603-8555, Japan.
Cancer Lett. 2006 Aug 18;240(1):83-93. doi: 10.1016/j.canlet.2005.08.030. Epub 2005 Oct 24.
The study aims at establishing a novel vaccine procedure, using bone marrow-derived DCs that have ingested apoptotic B16 melanoma (DCs(+)), alone or in combination with splenic T lymphocytes from a syngenic donor. Co-immunization with DCs(+) and T cells showed the highest antitumor potential against preestablished B16 tumor in mice, in which CTL and NK cytotoxicities were drastically elevated, while either DCs(+) alone, naive DCs (DCs(-)) alone, or a mixture of DCs(-) and T cells induced less significant therapeutic outcomes. Use of extracellular matrix proteins elevated antitumor activity of DC(-)/T cell vaccine. Compared with the CD8(+) cells, the CD4(+)T cells more remarkably improved the efficacy of DC-based immunotherapy. The present system may be a feasible therapeutic modality to eradicate malignancies including melanoma.
本研究旨在建立一种新型疫苗程序，使用摄取了凋亡性B16黑色素瘤的骨髓来源树突状细胞（DCs(+)），单独使用或与同基因供体的脾T淋巴细胞联合使用。DCs(+)与T细胞共同免疫显示出对小鼠体内预先建立的B16肿瘤具有最高的抗肿瘤潜力，其中CTL和NK细胞毒性显著升高，而单独的DCs(+)、未成熟DCs（DCs(-)）或DCs(-)与T细胞的混合物诱导的治疗效果则不太显著。细胞外基质蛋白的使用提高了DC(-)/T细胞疫苗的抗肿瘤活性。与CD8(+)细胞相比，CD4(+)T细胞更显著地提高了基于DC的免疫治疗效果。本系统可能是根除包括黑色素瘤在内的恶性肿瘤的一种可行治疗方式。
